Thursday, November 21, 2024 11/21/2024

Econometric Evaluation of Earned Income Tax Credit Expansions on Type 2 Diabetes-Related Behavior and Outcomes: Identifying effective leverage opportunities in social policy changes for health equity

Award Number: P30DK111024
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

OVERVIEW: PROJECT SUMMARY / ABSTRACT While considerable evidence is available for prevention and care of diabetes, huge gaps remain in equitable and sustainable translation of this knowledge into practice and policy in clinical and community settings. To close these gaps, the Georgia Center for Diabetes Translation Research (GCDTR), has leveraged the multidisciplinary expertise and experience in Atlanta, by bringing together collaborations among researchers from several leading institutions, namely, Emory's Rollins School of Public Health, School of Medicine, School of Nursing, and Goizueta Business School; Georgia Institute of Technology; and Morehouse School of Medicine. Having successfully expanded the translation research (from $15 to $33 million annually), and investigators (from 38 to 102 members, including 26 newly recruited diabetes faculty) bases, GCDTR will embrace the vision of equity and strive to close the gaps in diabetes prevention and care across demographic and comorbid groups, especially in socially, economically, and ethnically disadvantaged populations. GCDTR will include an Administrative Core A, seamlessly coordinating three interconnected translation research cores: (1) Core B, Design and Evaluation for Equity, emphasizing measurement and learning from previous experiences—both successes and failures—through appropriate metrics and evaluation and innovating for the future (design) to help stimulate progress; (2) Core C, Socio-ecological and Behavioral Sciences for Equity, bringing a wealth of interdisciplinary experiences in developing theoretically-based interventions and innovative, technology-driven engagement methodologies promoting the adoption and maintenance of health- promoting behaviors among vulnerable populations; and (3) a Regional Core, Technologies Advancing Translation and Equity, and expanding partnerships to include institution in neighboring Florida and Tennessee – southeastern states that have historically had large underserved areas and populations at high risk for diabetes. Enrichment and Pilot and Feasibility Programs will continue to enhance young and transitioning investigators' capacity to be competitive for NIH funds in translation research and have impact on diabetes prevention and care. This multi-institutional, multidisciplinary center, involving over 120 members, brings considerable breadth and depth of research expertise, a substantial research base, and leverages several NIH-funded Centers, namely, the Georgia Clinical and Translational Science Alliance (GaCTSA), Center for AIDS Research (CFAR), and the AHA-funded Morehouse/Emory Center for Health Equity. Proximity to and relationships with the Division of Diabetes Translation at the US Centers for Disease Control and Prevention (CDC) also offers GCDTR many unique assets. Furthermore, we have instituted several innovations, and obtained strong institutional support and commitments (totaling $857,500 over 5 years), and leveraged a variety of doctoral and post-doctoral programs to develop an efficient, effective, and integrated center.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	9	11/5/2024	NON-COMPETING CONTINUATION	$0
2025	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	9	10/22/2024	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $845,689 )
2024	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	9	9/6/2024	SUPPLEMENT FOR EXPANSION	$75,864
2024	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	9	8/30/2024	NON-COMPETING CONTINUATION	$769,825
														Subtotal = $845,689

Issue Date FY: 2023 ( Subtotal = $774,947 )
2023	2023	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	006	8	8/31/2023	NON-COMPETING CONTINUATION	$774,947
2023	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Trans-NIH Research Support	005	7	8/31/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	7	4/21/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	6	11/23/2022	SUPPLEMENT FOR EXPANSION	$0
2023	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	004	6	8/31/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2020	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Trans-NIH Research Support	003	5	8/31/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2020	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Trans-NIH Research Support	002	5	6/22/2023	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $774,947

Issue Date FY: 2022 ( Subtotal = $2,529,153 )
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Trans-NIH Research Support	003	7	8/31/2022	SUPPLEMENT FOR EXPANSION	$1,194,851
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	7	8/30/2022	NON-COMPETING CONTINUATION	$796,968
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	004	7	9/1/2022	SUPPLEMENT FOR EXPANSION	$537,334
2022	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	6	3/21/2022	COMPETING CONTINUATION	$229,283
2022	2020	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	3/21/2022	NON-COMPETING CONTINUATION	-$229,283
														Subtotal = $2,529,153

Issue Date FY: 2021 ( Subtotal = $1,049,999 )
2021	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	003	6	8/27/2021	SUPPLEMENT FOR EXPANSION	$300,000
2021	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	6	8/16/2021	COMPETING CONTINUATION	$749,999
2021	2020	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Trans-NIH Research Support	001	5	4/28/2021	SUPPLEMENT FOR EXPANSION	$0
2021	2020	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Trans-NIH Research Support	004	5	8/30/2021	SUPPLEMENT FOR EXPANSION	$0
2021	2020	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	11/5/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,049,999

Issue Date FY: 2020 ( Subtotal = $4,266,839 )
2020	2020	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	7/30/2020	NON-COMPETING CONTINUATION	$480,605
2020	2020	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Trans-NIH Research Support	001	5	9/22/2020	SUPPLEMENT FOR EXPANSION	$3,786,234
														Subtotal = $4,266,839

Issue Date FY: 2019 ( Subtotal = $704,790 )
2019	2019	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	9/4/2019	NON-COMPETING CONTINUATION	$486,393
2019	2019	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	4	9/5/2019	SUPPLEMENT FOR EXPANSION	$218,397
														Subtotal = $704,790

Issue Date FY: 2018 ( Subtotal = $633,017 )
2018	2018	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	8/31/2018	NON-COMPETING CONTINUATION	$633,017
														Subtotal = $633,017

Issue Date FY: 2017 ( Subtotal = $645,243 )
2017	2017	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	8/18/2017	NON-COMPETING CONTINUATION	$504,843
2017	2017	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	2	9/15/2017	SUPPLEMENT FOR EXPANSION	$140,400
														Subtotal = $645,243

Issue Date FY: 2016 ( Subtotal = $532,185 )
2016	2016	EMORY UNIVERSITY	1784 N DECATUR RD,S 530 NDBLDG	ATLANTA	GA	30322	DEKALB	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/16/2016	NEW	$532,185
														Subtotal = $532,185

Grand Total All Awards = $11,981,862

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Econometric Evaluation of Earned Income Tax Credit Expansions on Type 2 Diabetes-Related Behavior and Outcomes: Identifying effective leverage opportunities in social policy changes for health equity

Award Number: P30DK111024

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer